Holen Sie sich die Stockscreener-App
449.74
2.19%
-10.07
Handel nachbörslich:
447.35
-2.39
-0.53%
Schlusskurs vom Vortag:
$459.81
Offen:
$459.57
24-Stunden-Volumen:
364.53K
Relative Volume:
1.12
Marktkapitalisierung:
$10.39B
Einnahmen:
$1.13B
Nettoeinkommen (Verlust:
$-309.44M
KGV:
-35.14
EPS:
-12.8001
Netto-Cashflow:
$-275.41M
1W Leistung:
-4.67%
1M Leistung:
-15.00%
6M Leistung:
-14.30%
1J Leistung:
+1.72%
1-Tages-Spanne:
$446.61
$462.62
1-Wochen-Bereich:
$446.61
$478.85
52-Wochen-Spanne:
$393.61
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Firmenname
Madrigal Pharmaceuticals Inc
Sektor
Branche
Telefon
404-380-9263
Adresse
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
449.74 | 10.39B | 1.13B | -309.44M | -275.41M | -12.80 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-24 | Fortgesetzt | Goldman | Buy |
| 2026-09-23 | Eingeleitet | Citigroup | Buy |
| 2026-08-04 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2026-07-27 | Eingeleitet | Wells Fargo | Overweight |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-06 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-11-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-11-03 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-09-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-28 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-06-28 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-04-22 | Eingeleitet | BofA Securities | Underperform |
| 2024-03-15 | Hochstufung | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-02-26 | Herabstufung | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | Bestätigt | Oppenheimer | Outperform |
| 2022-12-19 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-19 | Bestätigt | Piper Sandler | Overweight |
| 2022-12-19 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Fortgesetzt | Goldman | Buy |
| 2020-11-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-11-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-01-30 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-01-09 | Hochstufung | UBS | Neutral → Buy |
| 2019-11-07 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-25 | Eingeleitet | Stifel | Hold |
| 2019-06-10 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Neutral |
| 2018-11-19 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Eingeleitet | Citigroup | Buy |
| 2018-08-06 | Herabstufung | Goldman | Buy → Neutral |
| 2018-06-28 | Eingeleitet | Raymond James | Mkt Perform |
Alle ansehen
Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten
Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care? - Zacks Investment Research
Madrigal Pharmaceuticals stock gets fresh Rezdiffra data - AD HOC NEWS
A liver drug improved disease measures across several genetic risk groups - Stock Titan
Under an automatic trading plan, director Paul Friedman proposes to sell shares in Madrigal Pharmaceuticals (MDGL). - Stock Titan
Madrigal Grants Equity Awards to 27 New Employees - MyChesCo
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Understanding Momentum Shifts in (MDGL) - Stock Traders Daily
Madrigal Pharmaceuticals (NASDAQ: MDGL) insider plans another stock sale after recent multimillion-dollar trades - stocktitan.net
Madrigal Pharma CEO William John Sibold disposes of common shares worth $4.16 million - Bitget
Madrigal Pharmaceuticals, Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Madrigal at cantor healthcare conference: growth, access and pipeline By Investing.com - Investing.com Nigeria
Madrigal at cantor healthcare conference: growth, access and pipeline By Investing.com - Investing.com Canada
Madrigal at cantor healthcare conference: growth, access and pipeline - investing.com
Madrigal at cantor healthcare conference: growth, access and pipeline By Investing.com - Investing.com UK
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You? - Yahoo Finance
Madrigal Pharmaceuticals, Inc. Rings the Closing Bell - Nasdaq
Madrigal Pharmaceuticals (NASDAQ: MDGL) exec plans $3.4M stock sale for tax withholding - stocktitan.net
September 2026 Nasdaq Stock Market Bell Ceremonies - Nasdaq
Madrigal Pharmaceuticals (MDGL) Stock Analysis: A 25% Upside Potential In Biotech Innovation - DirectorsTalk Interviews
Madrigal to Put MASH Drug Strategy Before Investors at Cantor - MyChesCo
Madrigal Pharmaceuticals (MDGL) Leads Healthcare CapEx Growth Am - GuruFocus
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference - manilatimes.net
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference - GlobeNewswire
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference - Yahoo Finance
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: A 27% Upside Potential Amid Biotech Innovation - DirectorsTalk Interviews
Madrigal Grants Stock Awards to 13 New Employees - MyChesCo
Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off - Yahoo Finance
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Report: Analysts See 31% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
When Will Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Become Profitable? - 富途牛牛
Madrigal Pharmaceuticals' General Counsel Executes Automatic Sale of 664 Shares to Cover Tax Withholding - Kalkine Media
Shannon Kelley Sells 664 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock - MarketBeat
Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule - TradingView
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Madrigal (NASDAQ: MDGL) GC has 664 shares sold for RSU taxes - stocktitan.net
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Madrigal (NASDAQ: MDGL) officer plans $337K sell-to-cover trade - stocktitan.net
Madrigal Pharmaceuticals (MDGL) Stock May Look Cheap On Sales But Risky On Cash Flow - simplywall.st
Exploring 3 High Growth Tech Stocks In The US Market - Sahm
Madrigal Adds J&J R&D Chief to Board as MASH Push Expands - MyChesCo
Madrigal (NASDAQ: MDGL) awards Reed 647 RSUs and options on 1,078 shares - stocktitan.net
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: A Biotech Powerhouse with 33.59% Upside Potential - DirectorsTalk Interviews
2,410 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Acquired by State of Wyoming - MarketBeat
Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands - MarketBeat
Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands - Yahoo Finance
Madrigal Uses Equity Awards to Recruit 10 Employees - MyChesCo
Madrigal Pharmaceuticals Inc (0JXI) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Madrigal Pharmaceuticals Adds Renowned Leader to Board - The Globe and Mail
Dimensional Fund Advisors LP Has $4.46 Million Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals Appoints Dr. John C. Reed to Expanded Board with Detailed Compensation Plan - Kalkine Media
Finanzdaten der Madrigal Pharmaceuticals Inc-Aktie (MDGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Madrigal Pharmaceuticals Inc-Aktie (MDGL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sibold William John | President and CEO |
Sep 11 '26 |
Sale |
542.39 |
5,221 |
2,831,801 |
197,746 |
| WILLIAM SIBOLD | Director |
Sep 11 '26 |
Proposed Sale |
533.12 |
5,221 |
2,783,420 |
0 |
| William John Sibold | Officer and Director |
Sep 09 '26 |
Proposed Sale |
534.16 |
6,362 |
3,398,326 |
0 |
| Sibold William John | President and CEO |
Sep 09 '26 |
Sale |
535.59 |
6,362 |
3,407,397 |
202,967 |
| Kelley Shannon T | General Counsel |
Aug 17 '26 |
Sale |
514.97 |
664 |
341,940 |
11,474 |
| Shannon Kelley | Officer |
Aug 17 '26 |
Proposed Sale |
507.56 |
664 |
337,020 |
0 |
| Sibold William John | President and CEO |
Jul 20 '26 |
Sale |
547.30 |
2,500 |
1,368,253 |
209,329 |
| William Sibold | Officer and Director |
Jul 20 '26 |
Proposed Sale |
553.48 |
2,500 |
1,383,700 |
0 |
| Soergel David | Chief Medical Officer |
Jun 01 '26 |
Sale |
495.74 |
1,042 |
516,561 |
10,033 |
| DAVID SOERGEL | Officer |
Jun 01 '26 |
Proposed Sale |
497.27 |
1,042 |
518,155 |
0 |
2.44%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):